Viral Vector Process Development Summit on January 31-February 02, 2023 in Boston, United States

As cell and gene therapy and genomic medicine pipeline continues to mature, process development for viral vector is becoming critical for drug developers for the next phase, to deliver a quality, transformative cure to patients with affordability. The recent investments such as Novartis-Samsung Biologics $81m contract for viral vector manufacturing, Resilience raising $625m towards biomanufacturing capabilities including stable cell lines for viral vector production pave the foundation for scientific and technology innovations.

With better understanding of these novel nanoparticles, developability and cell line development, the ability to optimize AAV, LV formulation and define robust CQAs are critical to drug developers' ability to increase scalability with efficiency, reduce cost of goods and most importantly, ensure product quality control for patients.

The inaugural Viral Vector Process Development Summit is premier platform tailored for Upstream and Downstream Process Development Scientists, Viral Vector Technology, CMC and Production Leads to share their lessons learned and inspirations to overcome bottlenecks. The 3-days summit, joined by the likes of Bristol Myers Squibb, Boehringer Ingelheim, Vertex, Takeda, Ultragenyx will equip you with:

- Novel strategies to optimize upstream viral vector processes with improved cell line suspension

- Bridging the gap between USP and DSP, and explore purification techniques to yield a pure viral vector drug product

- Enhance your formulation for a stable viral vector product – compare and contrast viral vector process development for cell and gene therapies

- Reduce impurity and maximize process development robustness for greater process control and quality

- Navigate the fast-evolving regulatory landscape to achieve GMP during scale up and scale out

- Join 60+ senior leaders at this unique forum to benchmark your current approach to deliver a safe, efficacious and economically viable cure for patients at scale!

URLs:

Tickets: https://go.evvnt.com/1322215-2?pid=10008 

Website: https://go.evvnt.com/1322215-3?pid=10008

Time: 9:00 am - 4:30 pm

Prices:

Conference + 3 Workshops - Drug Developer: USD 4496.00,

Conference + 2 Workshops - Drug Developer: USD 3997.00,

Conference + 1 Workshop - Drug Developer: USD 3498.00,

Conference Only - Drug Developer: USD 2999.00,

Conference + 3 Workshops - Vendor: USD 5396.00,

Conference + 2 Workshops - Vendor: USD 4797.00,

Conference + 1 Workshop - Vendor: USD 4198.00,

Conference Only - Vendor: USD 3599.00,

Conference + 3 Workshops - Academic: USD 3796.00,

Conference + 2 Workshops - Academic: USD 3397.00

Speakers: Rajiv Gangurde | Chief Technology Officer | SparingVision, Susan D'Costa | Executive VP and Global Head, Technology | Alcyone Therapeutics, John Moscariello | Executive Director, Viral Vector and Gene Editing Process Development | Bristol Myers Squibb, Anadita Seth | Vice President, Process and Analytical Development | Neurogene, Gael Debauve | Head, Gene CMC Therapy Analytics, UCB and Member, AAV Manufacturing Expert Panel | US Pharmacopeia, Jessie Sun | Director, Upstream Process Development | Ultragenyx Pharmaceutical, Matthew Weaver | Senior Director, Process Development | Spirovant Sciences, Elena Peletskaya | Senior Director, Portfolio Technical Strategy | Bristol Myers Squibb, Seth Levy | Director, Bioprocess Development | Modalis Therapeutics, Stephen Zano | Associate Director, Early Research and Process Development | Sarepta Therapeutics, Ashutosh Gupta | Head, Vector Production | Takeda, Saurabh Gautam | Lab Head, Bioprocess Development Viral Vectors and Vaccines | Boehringer Ingelheim, Shamik Sharma | Director, Cell Culture Development | Voyager Therapeutics, Xiaozhi Ren | Director, Cell Line and Process Development | Vedere Bio II, Xiaolong Lu | Director, Downstream Process Development, Gene Therapy Program | University of Pennsylvania, Patrick Westmoreland | Principal Scientist, Viral Vector and Gene Editing Process Development | Bristol Myers Squibb, Jan Panteli | Director, Upstream Process Development | Ultragenyx Pharmaceutical, Ashish Saksule | Principal Scientist, Vector Core Lead | Vertex Pharmaceuticals, Adnan Kapadia | Scientist, Vector Process Development | 2Seventy Bio, Julia Rohlhill | Scientist, Viral Vector Process Development | Bristol Myers Squibb